A0200000
Acetylsalicylic acid
European Pharmacopoeia (EP) Reference Standard
Synonyma:
2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin
Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
About This Item
Lineární vzorec:
2-(CH3CO2)C6H4CO2H
Číslo CAS:
Molekulová hmotnost:
180.16
Beilstein/REAXYS Number:
779271
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Doporučené produkty
grade
pharmaceutical primary standard
API family
aspirin
manufacturer/tradename
EDQM
mp
134-136 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
CC(=O)Oc1ccccc1C(O)=O
InChI
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
InChI key
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
Gene Information
human ... PTGS1(5742) , PTGS2(5743)
Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Acetylsalicylic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Related product
Č. produktu
Popis
Stanovení ceny
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk_germany
WGK 1
flash_point_f
482.0 °F
flash_point_c
250 °C
Vyberte jednu z posledních verzí:
Osvědčení o analýze (COA)
Lot/Batch Number
Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.
Potřebujete-li pomoc, obraťte se na Zákaznická podpora
Již tento produkt vlastníte?
Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.
Zákazníci si také prohlíželi
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
Gwen M C Masclee et al.
Gastroenterology, 147(4), 784-792 (2014-06-18)
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
T N Bonten et al.
Thrombosis and haemostasis, 112(6), 1209-1218 (2014-09-12)
The risk of acute cardiovascular events is highest during morning hours, and platelet activity peaks during morning hours. The effect of timing of aspirin intake on circadian rhythm and morning peak of platelet reactivity is not known. It was our
J W Eikelboom et al.
Journal of thrombosis and haemostasis : JTH, 3(12), 2649-2655 (2005-12-20)
We aimed to determine whether adding clopidogrel to aspirin in patients at high risk of future cardiovascular events would suppress laboratory measures of the antiplatelet effects of aspirin; and have greater platelet inhibitory effects in patients with the least inhibition
Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..
Obraťte se na technický servis.